Crossmark

The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-025-14185-x

Published Online: 2025-04-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deng, Wei https://orcid.org/0009-0002-9468-9234
Xie, Jin

Wang, Tao

Luo, Laihui https://orcid.org/0000-0003-3351-2187
Zhu, Guoqing

Xiao, Yongqiang https://orcid.org/0000-0003-2626-9182
Tao, Jiahao

Lin, Liucong

Ge, Xian

Wen, Wu

Wang, Minglong

Yu, Bin

Liu, Yu

Luo, Rongguang

Wan, Renhua

Hu, Zhigao

Shan, Renfeng https://orcid.org/0000-0001-5016-7448
License Information

Text and Data Mining valid from 2025-04-25

Version of Record valid from 2025-04-25
More Information

Article History

Received: 2 April 2024

Accepted: 18 April 2025

First Online: 25 April 2025

Declarations

:

: The studies involving human participants were reviewed and approved by the Ethics Committee of the first affiliated hospital of Nanchang University, Nanchang, China. No. (2022) CDYFYYLK (06–009). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below